Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., says that the power of the human immune system can be successfully harnessed to kill malignant tumors and to prevent their recurrence. Dr. Michael Har-Noy says that preliminary data indicates that AlloStimTM, his company’s lead product, has powerful anti-tumor activity against a wide range of malignancies. Dr. Michael Har-Noy is now conducting a Phase I/II trial that combine AlloStimTM with Chaperone Rich Protein Lysate (CRCL). He hopes this combination will both eradicate malignant tumors and prevent their recurrence. More information about Dr. Michael Har-Noy’s landmark phase I/II trial of CRCL-AlloVaxTM can be found at www.immunocare.net.
